Cladribine versus fingolimod, natalizumab and interferon for multiple sclerosis

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F18%3A10381915" target="_blank" >RIV/00216208:11110/18:10381915 - isvavai.cz</a>

Alternative codes found

RIV/00064165:_____/18:10381915

Result on the web

<a href="https://doi.org/10.1177/1352458517728812" target="_blank" >https://doi.org/10.1177/1352458517728812</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1177/1352458517728812" target="_blank" >10.1177/1352458517728812</a>

Result language

angličtina

Original language name

Cladribine versus fingolimod, natalizumab and interferon for multiple sclerosis

Original language description

Objective: This propensity score-matched analysis from MSBase compared the effectiveness of cladribine with interferon , fingolimod or natalizumab. Methods: We identified all patients with relapse-onset multiple sclerosis, exposure to the study therapies and 1-year on-treatment follow-up from MSBase. Three pairwise propensity score-matched analyses compared treatment outcomes over 1year. The outcomes were hazards of first relapse, disability accumulation and disability improvement events. Sensitivity analyses were completed. Results: The cohorts consisted of 37 (cladribine), 1940 (interferon), 1892 (fingolimod) and 1410 patients (natalizumab). The probability of experiencing a relapse on cladribine was lower than on interferon (p=0.05), similar to fingolimod (p=0.31) and higher than on natalizumab (p=0.042). The probability of disability accumulation on cladribine was similar to interferon (p=0.37) and fingolimod (p=0.089) but greater than natalizumab (p=0.021). The probability of disability improvement was higher on cladribine than interferon (p=0.00017), fingolimod (p=0.0025) or natalizumab (p=0.00099). Sensitivity analyses largely confirmed the above results. Conclusion: Cladribine is an effective therapy for relapse-onset multiple sclerosis. Its effect on relapses is comparable to fingolimod and its effect on disability accrual is comparable to interferon and fingolimod. Cladribine may potentially associate with superior recovery from disability relative to interferon, fingolimod and natalizumab.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30103 - Neurosciences (including psychophysiology)

Project

—

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2018

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Multiple Sclerosis Journal

ISSN

1352-4585

e-ISSN

—

Volume of the periodical

24

Issue of the periodical within the volume

12

Country of publishing house

GB - UNITED KINGDOM

Number of pages

10

Pages from-to

1617-1626

UT code for WoS article

000447789100014

EID of the result in the Scopus database

2-s2.0-85043391908